Bonesupport Holding (BONEX) Stock Overview
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BONEX Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 229.20 |
| 52 Week High | SEK 346.40 |
| 52 Week Low | SEK 165.00 |
| Beta | 0.45 |
| 1 Month Change | 14.26% |
| 3 Month Change | 24.03% |
| 1 Year Change | -23.24% |
| 3 Year Change | 154.53% |
| 5 Year Change | 297.23% |
| Change since IPO | 616.25% |
Recent News & Updates
Recent updates
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Feb 12
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Nov 22Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Oct 28Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Aug 25Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Jul 23Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Jun 28Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
Apr 28
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Mar 01Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
Oct 31Shareholder Returns
| BONEX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 7.0% | 0.7% | 3.3% |
| 1Y | -23.2% | 30.5% | 21.8% |
Return vs Industry: BONEX underperformed the Swedish Biotechs industry which returned 34.8% over the past year.
Return vs Market: BONEX underperformed the Swedish Market which returned 28.3% over the past year.
Price Volatility
| BONEX volatility | |
|---|---|
| BONEX Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: BONEX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BONEX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 148 | Torbjorn Skold | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BONEX fundamental statistics | |
|---|---|
| Market cap | SEK 15.30b |
| Earnings (TTM) | SEK 142.15m |
| Revenue (TTM) | SEK 1.17b |
Is BONEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONEX income statement (TTM) | |
|---|---|
| Revenue | SEK 1.17b |
| Cost of Revenue | SEK 87.33m |
| Gross Profit | SEK 1.09b |
| Other Expenses | SEK 945.17m |
| Earnings | SEK 142.15m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 22, 2026
| Earnings per share (EPS) | 2.13 |
| Gross Margin | 92.57% |
| Net Profit Margin | 12.10% |
| Debt/Equity Ratio | 0% |
How did BONEX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 12:19 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonesupport Holding AB (publ) is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |